AMCo – new beginnings

20th November 2013

John Beighton

• Medical Rep/Regional Manager - Smith Kline and French UK– 1981-1990

• Various sales and marketing jobs – SmithKline Beecham UK– 1990-1997

• Commercial Director – APS Berk/Teva UK– 1997-2002

• Managing Director Teva UK– 2002-2009

• VP Global Business Optimisation – Teva Pharmaceutical Ind.– 2009 – 2010

• CEO AMCo– 2010 to date

Presenter

Company Origins“G word”

Mar-12

Aug-12Oct-12

Jan-13

£465m£367m

Rebranding

Refinancing

1991

80%

38

£106million

2012 Sales

Revenues in the United Kingdom

Countries with commercial presence

Established Brands and GenericsVirtual Business Model (R&D, Manufacturing outsourced)

------

------

------

------

------

------

------

------

------

------

Established 1991, Headquarters in South London Acquired by Cinven (Private Equity) August 2012 for £465 million

Rx

Mercury Pharma

2002

34%

100+

£109million

2012 Sales

Revenues in the United Kingdom

Countries with commercial presence

Established Brands and GenericsVirtual Business Model (R&D, Manufacturing outsourced)

------

------

------

------

------

------

------

------

------

------

Established 2002, Headquarters East of London. Acquired by Cinven (Private Equity) August 2012 for £367 million

Rx

Amdipharm

2013 Expected revenues (15% Growth)

------

------

------

------

------

------

------

------

------

------------

------

Amdipharm Mercury (AMCo)

2013

60%

112

£248million

Rx Established Brands and GenericsVirtual Business Model (R&D, Manufacturing outsourced)

Revenues in the United Kingdom

Countries with commercial presence

Combined group rebranded AMCo in March 2013UK Office to be relocated to Central London

1992

1999

2001

2004

2006

2007

2008

2013

Macrodantin, Furadantin, Macrobid, Furabid

nitrofurantoin £18m

18 Countries

figures quoted are 2013 forecast revenues

Eltroxinlevothyroxine

£27m13 Countries

Liothyronineliothyronine

£10m10 Countries

Neomercazolecarbimazole

£12m20 Countries

Fucithalmicfusidic acid

£26m>90 Countries

Hygrotonchlortalidone

£5m12 Countries

Ludiomilmaprotiline

£3m25 Countries

Cafergotergotamine

£2m26 Countries

Diamoxacetazolamide

£5m27 Countries

Hytrinterazosin

£5m21 Countries

Erythrocinerythromicin

£16m32 Countries

Akinetonbiperiden

£7m21 Countries

Transactflurbiprofen

£8m2 Countries

Acquisition History

Management Team

Guy ClarkStrategic

Development

Robert SullyGeneralCounsel

Vikram KamathFinance Director

John BeightonCEO

John CowellHuman

Resources

Bharat KarbalMedical &

Regulatory

Jane HillUK

Commercial

Karl BelkGlobal

Operations

Simon TuckerInternational Commercial

Brian McEwanManaging Director

Amdipharm

Peter van TiggelenCFO

Sales History by Company2010 to 2013 est.

2013

2012

2011

2010

£0 £50 £100 £150 £200 £250

£126

£106

£88

£79

£122

£109

£113

£125

Mercury Amdipharm

Company Performance

Millions

Top 10 Molecules (Percentage of 2012 revenue)

Levothyroxine11%

Erythromicin8%

Nitrofurantoin7%

Flurbiprofen5%

Codeine +paracetamol

5%

Biperiden4%

Liothyronine4%

Carbimazole4%

Prednisolone4%

Cyclizine3%

AMCo Strategy

• Consolidate strong position in UK– Off-patent brands and niche products

UK Commercial Team

Jane HillUK Commercial

Director

Jeremy DevaneyHospitals

Jenna PritchardNational Accounts

Neil CookPromoted Products

AMCo Strategy

• Focus on 5 Business Action Plans– Operational Excellence– Culture and Integration– Compliance – Quality and Reputation– International Excellence– Strategic Growth

Global Coverage

AMCo offices/direct presence

Distributor network

>50% of sales in UK

International Excellence

AMCo offices/direct presence

Distributor network

Target markets – direct presence

Licensing Development AcquisitionDedicated business development team focused on driving revenue and profit growth

BrandsPrimary & Secondary Care

•Low Competition•Stable Revenues and Profit•Multiple Markets•Growth Opportunities

Geographic ExpansionCompanies & Products

•Company acquisitions•Build out in Target Markets•Portfolio Optimisation•Distributor consolidation

Therapeutic FocusPrimary & Secondary Care

•Ophthalmology•Endocrinology•Urology•Infectious Diseases•Pain & Anaesthesia

Strategic Growth

Generics Primary & Secondary Care

•Low Competition•Barriers to Entry•Branded Generics•Sustainable Pricing

Strategic Development Activity• Portfolio Optimisation – registering existing AMCo products into new markets where the

product isn’t currently registered or sold, and using the existing manufacturers to make the product

• Product Development – creating new products with a contract development partner, whereby AMCo retains full ownership rights to the product, and freedom to choose who to manufacture the product

• In-Licensing – buying the rights to sell a third party’s product in a defined territory, and agreeing for the licensor to supply the product to AMCo for an agreed period of time (typically 5 years)

• Product Acquisitions – buying the permanent rights to own an existing product, in a defined territory (sometimes global e.g. Fucithalmic). The seller may wish to continue making the product, but more often would require AMCo to find a new supplier within 2-3 years

United Kingdom

No. 1 Croydon12-16 Addiscombe RoadCroydon CR0 0XT

+44 (0)20 8649 8500

Committed to being a socially responsible company, we support:

Ireland

102 Block BThe Crescent BuildingNorthwood SantryDublin 9

+353 (0)1 6971640

India

101 Vedanta 779 Makwana RoadMarol Andheri East Mumbai 400 059

+91 22 6678 4444

www.amcolimited.com